253 related articles for article (PubMed ID: 17317065)
1. Evaluation of the nephrotoxicity of iodixanol in patients with predisposing factors to contrast medium induced nephropathy referred for contrast enhanced computed tomography.
Sandstede JJ; Roth A; Machann W; Kaupert C; Hahn D
Eur J Radiol; 2007 Jul; 63(1):120-3. PubMed ID: 17317065
[TBL] [Abstract][Full Text] [Related]
2. Iso-osmolality versus low-osmolality iodinated contrast medium at intravenous contrast-enhanced CT: effect on kidney function.
Nguyen SA; Suranyi P; Ravenel JG; Randall PK; Romano PB; Strom KA; Costello P; Schoepf UJ
Radiology; 2008 Jul; 248(1):97-105. PubMed ID: 18483232
[TBL] [Abstract][Full Text] [Related]
3. Nephrotoxic effects of iodixanol and iopromide in patients with abnormal renal function receiving N-acetylcysteine and hydration before coronary angiography and intervention: a randomized trial.
Juergens CP; Winter JP; Nguyen-Do P; Lo S; French JK; Hallani H; Fernandes C; Jepson N; Leung DY
Intern Med J; 2009 Jan; 39(1):25-31. PubMed ID: 18771430
[TBL] [Abstract][Full Text] [Related]
4. Contrast-induced nephropathy in patients with chronic kidney disease undergoing computed tomography: a double-blind comparison of iodixanol and iopamidol.
Barrett BJ; Katzberg RW; Thomsen HS; Chen N; Sahani D; Soulez G; Heiken JP; Lepanto L; Ni ZH; Ni ZH; Nelson R
Invest Radiol; 2006 Nov; 41(11):815-21. PubMed ID: 17035872
[TBL] [Abstract][Full Text] [Related]
5. Nephrotoxic effects in high-risk patients undergoing angiography.
Aspelin P; Aubry P; Fransson SG; Strasser R; Willenbrock R; Berg KJ;
N Engl J Med; 2003 Feb; 348(6):491-9. PubMed ID: 12571256
[TBL] [Abstract][Full Text] [Related]
6. Risk of contrast-induced nephropathy for patients receiving intravenous vs. intra-arterial iodixanol administration.
Tong GE; Kumar S; Chong KC; Shah N; Wong MJ; Zimmet JM; Wang ZJ; Yee J; Fu Y; Yeh BM
Abdom Radiol (NY); 2016 Jan; 41(1):91-9. PubMed ID: 26830615
[TBL] [Abstract][Full Text] [Related]
7. The PREDICT study: a randomized double-blind comparison of contrast-induced nephropathy after low- or isoosmolar contrast agent exposure.
Kuhn MJ; Chen N; Sahani DV; Reimer D; van Beek EJ; Heiken JP; So GJ
AJR Am J Roentgenol; 2008 Jul; 191(1):151-7. PubMed ID: 18562739
[TBL] [Abstract][Full Text] [Related]
8. Iodixanol: risk of subsequent contrast nephropathy in cancer patients with underlying renal insufficiency undergoing diagnostic computed tomography examinations.
Cheruvu B; Henning K; Mulligan J; Klippenstein D; Lawrence D; Gurtoo L; Gottlieb RH
J Comput Assist Tomogr; 2007; 31(4):493-8. PubMed ID: 17882021
[TBL] [Abstract][Full Text] [Related]
9. The ACTIVE Trial: comparison of the effects on renal function of iomeprol-400 and iodixanol-320 in patients with chronic kidney disease undergoing abdominal computed tomography.
Thomsen HS; Morcos SK; Erley CM; Grazioli L; Bonomo L; Ni Z; Romano L;
Invest Radiol; 2008 Mar; 43(3):170-8. PubMed ID: 18301313
[TBL] [Abstract][Full Text] [Related]
10. Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies.
Briguori C; Airoldi F; D'Andrea D; Bonizzoni E; Morici N; Focaccio A; Michev I; Montorfano M; Carlino M; Cosgrave J; Ricciardelli B; Colombo A
Circulation; 2007 Mar; 115(10):1211-7. PubMed ID: 17309916
[TBL] [Abstract][Full Text] [Related]
11. Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease.
Solomon RJ; Natarajan MK; Doucet S; Sharma SK; Staniloae CS; Katholi RE; Gelormini JL; Labinaz M; Moreyra AE;
Circulation; 2007 Jun; 115(25):3189-96. PubMed ID: 17562951
[TBL] [Abstract][Full Text] [Related]
12. Ionic low-osmolar versus nonionic iso-osmolar contrast media to obviate worsening nephropathy after angioplasty in chronic renal failure patients: the ICON (Ionic versus non-ionic Contrast to Obviate worsening Nephropathy after angioplasty in chronic renal failure patients) study.
Mehran R; Nikolsky E; Kirtane AJ; Caixeta A; Wong SC; Teirstein PS; Downey WE; Batchelor WB; Casterella PJ; Kim YH; Fahy M; Dangas GD
JACC Cardiovasc Interv; 2009 May; 2(5):415-21. PubMed ID: 19463464
[TBL] [Abstract][Full Text] [Related]
13. Iodixanol versus iopromide in cancer patients: Evidence from a randomized clinical trial.
Terrenato I; Sperati F; Musicco F; Pozzi AF; di Turi A; Caterino M; de Lutio di Castelguidone E; Setola SV; Bellomi M; Neumaier CE; Conti L; Cigliana G; Merola R; Antenucci A; Orlandi G; Giordano A; Barba M; Canitano S
J Cell Physiol; 2018 Mar; 233(3):2572-2580. PubMed ID: 28777459
[TBL] [Abstract][Full Text] [Related]
14. Nephrotoxicity of iso-osmolar versus low-osmolar contrast media is equal in low risk patients.
Feldkamp T; Baumgart D; Elsner M; Herget-Rosenthal S; Pietruck F; Erbel R; Philipp T; Kribben A
Clin Nephrol; 2006 Nov; 66(5):322-30. PubMed ID: 17140161
[TBL] [Abstract][Full Text] [Related]
15. Background fluctuation of kidney function versus contrast-induced nephrotoxicity.
Bruce RJ; Djamali A; Shinki K; Michel SJ; Fine JP; Pozniak MA
AJR Am J Roentgenol; 2009 Mar; 192(3):711-8. PubMed ID: 19234268
[TBL] [Abstract][Full Text] [Related]
16. Contrast-induced nephropathy in patients undergoing computed tomography (CONNECT) - a clinical problem in daily practice? A multicenter observational study.
Lencioni R; Fattori R; Morana G; Stacul F
Acta Radiol; 2010 Sep; 51(7):741-50. PubMed ID: 20707658
[TBL] [Abstract][Full Text] [Related]
17. [Effectiveness of nephroprotection by the selection of contrast media used during vascular interventions in patients with chronic renal failure?].
Schönefeld E; Höwler S; Osada N; Torsello G
Zentralbl Chir; 2011 Oct; 136(5):426-30. PubMed ID: 22009540
[TBL] [Abstract][Full Text] [Related]
18. Iso-osmolar radio contrast iodixanol in patients with chronic kidney disease.
Tadros GM; Malik JA; Manske CL; Kasiske BL; Dickinson SE; Herzog CA; Wilson RF; Das G; Panetta CJ
J Invasive Cardiol; 2005 Apr; 17(4):211-5. PubMed ID: 15831975
[TBL] [Abstract][Full Text] [Related]
19. Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial.
Jo SH; Youn TJ; Koo BK; Park JS; Kang HJ; Cho YS; Chung WY; Joo GW; Chae IH; Choi DJ; Oh BH; Lee MM; Park YB; Kim HS
J Am Coll Cardiol; 2006 Sep; 48(5):924-30. PubMed ID: 16949481
[TBL] [Abstract][Full Text] [Related]
20. Comparison of contrast-induced nephrotoxicity of iodixanol and iopromide in patients with renal insufficiency undergoing coronary angiography.
Shin DH; Choi DJ; Youn TJ; Yoon CH; Suh JW; Kim KI; Cho YS; Cho GY; Chae IH; Kim CH
Am J Cardiol; 2011 Jul; 108(2):189-94. PubMed ID: 21545991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
